Elucid Raises $80 Million In Series C Round Led By Elevage Medical Technologies

Nov 09, 2023•almost 2 years ago

Amount Raised

$80 Million

Round Type

series c

BostonManufacturingHealth Care

Investors

Elevage Medical Technologies

Description

Elucid, a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced it has raised $80 million in Series C funding. The round was led by Elevage Medical Technologies, with additional participation from industry strategics and existing investors. With this funding, Elucid is poised to capitalize on the past year’s momentum and expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease. This round brings the company’s total funding to $121 million since inception.

Company Information

Company

Elucid

Location

Boston, Massachusetts, United States

About

Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company’s PlaqueIQTM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFRCT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends